AbbVie was spun off from Abbott Laboratories on January 1, 2013, and relied heavily on Humira until the drug lost U.S. exclusivity in early 2023. In Q2 2026, Humira sales fell 35.9% to $756 million, while Skyrizi rose 24.4% to $5.505 billion and Rinvoq rose 24.5% to $2.525 billion. The quarterly dividend grew from $0.57 in 2016 to $1.73, with a forward annual dividend of $6.92 and a yield of roughly 2.30%. A $1,000 investment 10 years ago would be worth $7,464.50 including dividends, a 646.45% total return, versus 263.37% for the S&P 500 on a price-only basis. The article notes the shares closed at $197.99 on April 29, 2026, reached about $291.48 this morning, and trade above the average analyst target of $283.19, while also flagging negative shareholders' equity and a forward P/E of about 18.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
AbbViedividendspharmaceuticals
Open a keyword to see other news on the same topic.
Related news
- Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
Citadel Advisors, the hedge fund led by billionaire Ken Griffin, has been increasing its stake in AbbVie (ABBV) in recent months. In the second quarter, Citadel bought 2.7 million shares at an average price of $234.57, for about $633 million, bringing its holding to 3.2 million shares worth $909 million at the current price of about $284. The stock has risen about 24% this year and trades at 74 times trailing earnings, which some investors may view as expensive. The article's author nonetheless sees merit in AbbVie as a Dividend King that has raised its annual dividend for 50 consecutive years, currently $6.92 per share, a 2.43% dividend yield. The company has a strong brand lineup including Skyrizi, Rinvoq, Humira and Botox, and about 90 drugs and treatments in development; the FDA approved its once-daily Parkinson's pill Juvmo in September, and William Blair analysts expect its sales could reach as much as $1.4 billion annually by 2040. Of the 30 analysts tracked by Yahoo Finance, 24 rate the stock 'strong buy' or 'buy'.
- Great News for AbbVie Stock Investors
AbbVie (ABBV) shares have climbed 26% this year on strong financial performance, and the author sees a bright medium-term outlook. Skyrizi, the company's biggest growth driver, generated almost $10 billion in sales in the first half, up 27%, but its U.S. patents may begin expiring by 2033, potentially opening the door to cheaper biosimilars. On Oct. 19, AbbVie reported encouraging Phase 2a results for ABBV-466, which combines risankizumab and trosunilimab, though these must still be confirmed in Phase 3 studies. Its $10.9 billion cash acquisition of Apogee Therapeutics brought zumilokibart, which AbbVie hopes can challenge Dupixent (over $15 billion in annual sales), with maintenance injections possibly only every three or six months. Rinvoq should not face U.S. generics until 2037, and the author says AbbVie can deliver competitive long-term returns, with a forward yield of 2.5% versus the S&P 500's average of 1.1%.
- Forget High - Yield Traps : AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The article argues AbbVie (ABBV) is not a high-yield trap, since its free cash flow comfortably covers its $1.73-per-share quarterly dividend and most of its $70.8 billion debt is fixed-rate. The company has raised its dividend for 54 consecutive years, qualifying it as a Dividend King. Skyrizi and Rinvoq together brought in over $7.5 billion in Q2 2026, more than the $6.1 billion paid in dividends that quarter, and AbbVie has about 90 clinical-development programs, roughly 60 of them in mid- or late-stage studies. Its 2.5% yield is lower than before mainly because the share price has risen sharply, and the article notes that pipeline setbacks remain a risk.
- Forget High - Yield Traps : AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The article argues AbbVie is not a high-yield trap, because its free cash flow is sufficient to cover its quarterly dividend of $1.73 per share, and most of its $70.8 billion debt is in fixed-rate notes. AbbVie has raised its dividend for 54 consecutive years, qualifying it as a Dividend King, a group of stocks that have raised dividends for at least 50 years. Skyrizi and Rinvoq together brought in over $7.5 billion in the second quarter of 2026, more than the $6.1 billion paid in dividends that quarter, and the company has about 90 programs in development, around 60 of them in mid- or late-stage studies. The dividend yield of 2.5% is lower than before because the share price has risen faster than dividends, and the article notes that pipeline setbacks remain a risk.
- Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The article contrasts AbbVie with high-yield traps, arguing its free cash flow covers its quarterly dividend of $1.73 per share and that most of its $70.8 billion in debt is fixed-rate senior notes. AbbVie has raised its dividend for 54 consecutive years, qualifying it as a Dividend King, and Skyrizi and Rinvoq together brought in over $7.5 billion in the second quarter of 2026, more than the $6.1 billion paid in dividends that quarter. The company has roughly 90 programs in clinical development, around 60 in mid- or late-stage studies. Its 2.5% yield is lower than before because the share price has risen faster than dividends. The author notes that pipeline setbacks remain a risk.
- Dược Hậu Giang (DHG) Reports Lowest Quarterly Profit in Over 15 Years
Dược Hậu Giang (DHG) reported third-quarter 2026 after-tax profit down 53% to 98.5 billion VND, its lowest quarterly level since Q1 2011, as net revenue fell 11% to over 1,023 billion VND and selling expenses rose 23%. The company said some operating costs and corporate income tax increased, including the impact of global minimum tax rules. For the first nine months, net revenue grew nearly 2% to 3,584 billion VND and pre-tax profit reached 839 billion VND, or 83.3% of the full-year pre-tax target of 1,007 billion VND. As of 30 September 2026, total assets were down about 15% from the start of the year, with short-term financial investments down by over 1,021 billion VND. Financing outflows of over 1,307 billion VND mainly reflected the cash payment of the 2025 dividend at a 100% rate.
Related markets
Latest news
- Nvidia's relationship with China just got even more complicated as report says Jensen Huang was target of spy plot
Nvidia has struggled to gain a foothold in China because of US Commerce Department export restrictions in place since 2022. The New York Times reported that US intelligence believes Alice Huang, a leader at Nvidia customer Megaspeed with a well-documented relationship with Jensen Huang, acted as an intelligence asset and passed information to China's governing party, raising questions about information leakage from Nvidia. In December 2025, the Trump administration allowed some H200 chip exports after a $5 million lobbying push during the year, but H200 sales made up less than 1% of Nvidia's $89 billion second-quarter data center revenue, as Beijing blocked Chinese buyers from purchasing Nvidia chips. Nvidia said its forward outlook includes no China data center compute revenue. The article also describes a black-market trade smuggling chips through Southeast Asia and Blackwell B300 chips being openly sold on Douyin at millions of US dollars per server.
- Big Oil earnings are set to surge. Why investors may want to be cautious
The article says earnings at ExxonMobil, Chevron, Marathon Petroleum and ConocoPhillips are set to rise sharply, with EPS for XOM, CVX and COP expected to more than double from a year earlier. Marathon Petroleum's EPS estimate is $25.37 per share, versus $4.51 a year ago, driven by higher oil prices and a large crack spread on refined products, with sales expected to rise by $13 billion in one year. The author argues that guidance and capital spending plans may matter more than the earnings figures themselves. Citing BTIG analyst Jonathan Krinsky, the article notes the S&P Refining Index has risen nearly 160% in 2026, its best year in at least three decades, and that he expects at least consolidation, with a significant downside reversion considered more likely.
- Okta vs. UiPath: Which Technology Stock Is a Better Buy in 2026?
The article compares Okta (OKTA) and UiPath (PATH), two software companies with different models: Okta provides identity and access management, while UiPath offers an automation platform. Okta reported FY 2026 revenue of nearly $2.9 billion, up about 11.8%, and net income of close to $235.0 million versus $28.0 million a year earlier; free cash flow was nearly $863.0 million, though stock-based compensation was roughly 61.5% of operating cash flow. UiPath posted revenue of roughly $1.6 billion, up about 12.7%, net income of nearly $282.3 million and free cash flow of approximately $352.2 million, with stock-based compensation at roughly 78.3% of operating cash flow. The piece outlines Okta's competition and cybersecurity risks and UiPath's reliance on a limited number of large customers, and the author leans toward Okta, citing growing demand for identity security.
- Microsoft (MSFT) Expands Copilot In Education, Is The AI Upside Already Priced In?
McGraw Hill launched a plugin for Microsoft 365 Copilot that ties Copilot use to higher education workflows and licensed digital course materials. Microsoft's share price return was 17.71% over 90 days and 57.03% over 3 years, while the 1-year total shareholder return was slightly down 1.14%. A Simply Wall St narrative puts fair value at $419.91, below the last close of $531.01, and suggests Copilot optimism and strong cloud results may already be heavily reflected in the stock. On the other side, the article cites return on equity of 30.2%, a net profit margin of 40.3%, and a valuation model showing the stock trading about 22.5% below its estimate of future cash flow value. It also notes the stock looks expensive against a peer P/E average of 24.8x and significant insider selling over the past three months.
- Can This Number Push Booking Holdings Stock Higher?
Booking's top Genius members (Levels 2 and 3) made up more than 30% of active customers and a high 50% share of room nights in the June quarter, both up from a year earlier. Direct room nights kept growing, with the direct share of consumer room nights in the mid-60% range, though pressure on unpaid search traffic continued and large language model traffic stayed well below 1% of room nights. Booking plans a $100 million investment in Vayo, a new company offering a personal travel agent, announced October 14, 2026. The stock (BKNG) fell 29.0% in the year to October 28, 2026, while the S&P 500 returned 14.0%. For the September quarter, management guided room nights up 3% to 5% and gross bookings and revenue up 4% to 6%, versus June-quarter gains of 9% and 8%.
- ServiceNow just can't seem to escape the SaaSpocalypse — even after strong Q3 AI growth
A panel discussed ServiceNow after its results, where free cash flow rose but remaining performance obligations (RPO) came in modestly below expectations, and the company itself forecasts RPO growth to slow in the fourth quarter. CFO Gina Mastrantonio said AI net new business grew 65% year over year, beating expectations, which allowed the company to raise its full-year AI target to 1.7 billion while delivering AI value without a large capex investment. Julia said the market is not yet convinced, citing concerns about AI reducing seat counts, while Mastrantonio said ServiceNow's blended pricing covers both seats and usage. The stock was down 25% that day, which the speakers noted was the fourth straight quarter shares fell after a report.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.